This proposal, Clinical and Molecular Studies of Malignant Brain Tumors, builds upon my decade-long experience conducting highly productive patient-oriented research and successful mentoring of 26 neuro-oncology fellows at the Massachusetts General Hospital Cancer Center. The focus of the research strategy proposed in this application is to develop improved diagnostic and therapeutic approaches for malignant brain tumors. The protected time afforded to me during the first 5 years of this K24 award enabled me to complete multiple patient-oriented research projects, publish more than 95 papers, successfully compete for 3 peer-reviewed NIH and 2 foundation research grants as principal investigator, and mentor 11 current and past fellows and junior faculty members. Renewal of the award will enable me to expand my mentoring role to other oncology-related disciplines and to conduct patient-oriented research projects across new areas of neuro-oncology including brain metastases. Resources that will enable this expansion and assure success of a second 5-year period of funding include a neuro-oncology patient volume base that has doubled over the last 5 years, clinical trial accrual that has quadrupled over the last 5 years and a growing fellow and junior faculty group of investigators that provides an outstanding pool of potential mentees. In light of the expanding clinical volume it is imperative that I retain the ability to protect my time for patient-oriented research and mentoring. The expansion of my patient-oriented research and mentoring to other oncology-related disciplines will also enable me to secure additional peer-reviewed grant funding in new areas not currently represented in my active grant portfolio, which will further expand opportunities for future mentees. The award will enable me to further enhance my career as a patient-oriented researcher as well as my ability to mentor young investigators from neuro-oncology, medical oncology, neuroradiology/cancer imaging, transplant oncology and related disciplines.

Public Health Relevance

The award, Clinical and Molecular Studies of Malignant Brain Tumors, will enable new avenues of research into brain tumors and will expand the pool of young clinician-investigators who choose research careers dedicated to the study of these devastating types of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA125440-08
Application #
8717404
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
2007-08-01
Project End
2017-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81
Curry Jr, William T; Gorrepati, Ramana; Piesche, Matthias et al. (2016) Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 22:2885-96
Ohnishi, Takashi; Nakamura, Yuka; Tanaka, Toru et al. (2016) Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract 212:927-936
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Jordan, Justin T; Gerstner, Elizabeth R; Batchelor, Tracy T et al. (2016) Glioblastoma care in the elderly. Cancer 122:189-97
Andronesi, Ovidiu C; Loebel, Franziska; Bogner, Wolfgang et al. (2016) Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res 22:1632-41
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Batchelor, Tracy (2015) Managing primary central nervous system lymphoma. Clin Adv Hematol Oncol 13:438-40
Taylor, Jennie W; Dietrich, Jorg; Gerstner, Elizabeth R et al. (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121:557-63
Lee, Eudocia Q; Kaley, Thomas J; Duda, Dan G et al. (2015) A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res 21:3610-8

Showing the most recent 10 out of 54 publications